WE ARE EARLY PHASE I TO IIA
Each clinical trial brings new challenges and has to be seen from an individual perspective. The staff of CRS’s clinical pharmacological units dedicated itself to respond to these challenges for more than 40 years.
VALUES
Our patient’s well-being, their safety and respect for each individual is front and center with everything we do. We work with the highest possible standards of ethical and medical practice.
SPECIALIZED RESEARCH FACILITIES IN FOUR CITIES
Discover some of the world’s foremost recruiting facilities for renal and hepatic impairments as well as our other leading specialized research clinics.
OUR HISTORY
Founded in 2006, CRS cares most about precision early-phase research. In this time we have conducted thousands of trials for renowned pharma corporations and start-ups alike.
CRS IN A NUTSHELL
Since 40 years we tackle any type of clinical pharmacological trial.
REACHING OUT IS EASY AND FAST – LET’S TALK
Chairman of the Executive Board
located at CRS Mannheim
VP & Head of Business Development
located at CRS Management
SHORT APPROVAL TIMES
30 days from submission to approval due to our monocentric approach and parallel submission to ca and ec/irb.
RELIABLE RECRUITING
We provide fast recruitment of suitable patients with well established medical records.
FAST TRIAL CONDUCT
Average duration for a single dose trial in renal impaired patients is 4-6 months.
HIGH STANDARDISATION
Our setup allows the mono-centric conduct of complex pk trials with challenging requirements for the study population, avoiding inter-centre variability and guaranteeing highest quality according to phase-I standards.
PATIENT SAFETY
The infrastructure and expertise enables us to work according to the best ethical and medical practice regarding the vulnerable study population.
WE SCALE WITH YOUR BUSINESS
Our specialization in early-phase trials benefits all types of businesses in need of rapid and valid testing. This is true for start-up companies in need of assistance and expertise in this phase and large corporations alike.